The codon 55 polymorphism in the paraoxonase 1 gene is not associated with the risk of coronary heart disease in Asian Indians and Chinese.

[1]  D. Sanghera,et al.  Genetic polymorphism of paraoxonase and the risk of coronary heart disease. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[2]  P. Froguel,et al.  Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. , 1997, The Journal of clinical investigation.

[3]  M. Keifer,et al.  The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin , 1996, Nature Genetics.

[4]  D. Arveiler,et al.  The Gln/Arg polymorphism of human paraoxonase (PON 192) is not related to myocardial infarction in the ECTIM Study. , 1996, Atherosclerosis.

[5]  M. Jauhiainen,et al.  The Gln-Arg191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns. , 1996, The Journal of clinical investigation.

[6]  P. Edwards,et al.  The Yin and Yang of oxidation in the development of the fatty streak. A review based on the 1994 George Lyman Duff Memorial Lecture. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[7]  B. La Du,et al.  The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. , 1996, Genomics.

[8]  A. Marian,et al.  A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. , 1995, The Journal of clinical investigation.

[9]  J. Berliner,et al.  Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. , 1995, The Journal of clinical investigation.

[10]  A. Boulton,et al.  Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[11]  G. Charpentier,et al.  Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes , 1995, The Lancet.

[12]  P. Durrington,et al.  HDL, its enzymes and its potential to influence lipid peroxidation , 1995 .

[13]  J. Berliner,et al.  Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. , 1995, The Journal of clinical investigation.

[14]  C. Heng,et al.  Association of factor VII genotype with plasma factor VII activity and antigen levels in healthy Indian adults and interaction with triglycerides. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[15]  C. Furlong,et al.  Apolipoprotein J is associated with paraoxonase in human plasma. , 1994, Biochemistry.

[16]  Gopal Kanji,et al.  100 Statistical Tests , 1994 .

[17]  C. Abbott,et al.  Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. , 1993, Atherosclerosis.

[18]  V. Simeon,et al.  Heat inactivation of paraoxonase and arylesterase activities in human and rabbit serum. , 1993, Chemico-biological interactions.

[19]  S. Adkins,et al.  Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. , 1993, American journal of human genetics.

[20]  M. Blatter,et al.  Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45. Identity of K-45 with paraoxonase. , 1993, European journal of biochemistry.

[21]  D. Adler,et al.  The molecular basis of the human serum paraoxonase activity polymorphism , 1993, Nature Genetics.

[22]  R. Hamman,et al.  Two common polymorphisms in the APO A‐IV coding gene: Their evolution and linkage disequilibrium , 1992, Genetic epidemiology.

[23]  P. Winocour,et al.  Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. , 1991, Atherosclerosis.

[24]  C. Mannhalter,et al.  A rapid method for the isolation of genomic DNA from citrated whole blood. , 1991, The Biochemical journal.

[25]  S. Ratnam,et al.  Serum paraoxonase polymorphism in three populations of southeast Asia. , 1991, Human heredity.

[26]  C. Sing,et al.  Genetics of atherosclerosis. , 1990, Annual review of genetics.

[27]  C. Walker,et al.  Absence of "A"-esterase activity in the serum of a patient with Tangier disease. , 1989, Clinical biochemistry.

[28]  S. Humphries,et al.  DNA polymorphisms of the apolipoprotein genes--their use in the investigation of the genetic component of hyperlipidaemia and atherosclerosis. , 1988, Atherosclerosis.

[29]  J. Breslow.  Apolipoprotein genetic variation and human disease. , 1988, Physiological reviews.

[30]  C. Walker,et al.  Low A-esterase activity in serum of patients with fish-eye disease. , 1987, Clinical chemistry.

[31]  T. Diepgen,et al.  Interethnic differences in the detoxification of organophosphates: the human serum paraoxonase polymorphism. , 1986, Archives of toxicology. Supplement. = Archiv fur Toxikologie. Supplement.

[32]  K. Yagi,et al.  Lipid peroxide levels of serum lipoprotein fractions of diabetic patients. , 1981, Biochemical medicine.

[33]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.